About US
Contact us
-
Ex-HGS director draws fire for plugging anthrax drug at PentagonDid Human Genome Sciences unfairly benefit from its political connections? According to a Los Angeles Times investigation, former Navy Secretary Richard Danzig talked up HGS' anthrax drug raxibacumab2013/5/21
-
Australian judge kills Merck Vioxx class action settlementA federal judge in Australia has put the kibosh on a half-million-dollar settlement over ill effects of Merck's ($MRK) painkiller Vioxx, a drug that has spawned billions of dollars in litigation. Just2013/5/20
-
CFDA issues announcement on implementation of electronic supervision for drugs in the National Essential Medicine List (2012 edition)On May 9, 2013, China Food and Drug Administration (CFDA) issued an Announcement on implementation of electronic supervision for drugs in the National Essential Medicine List (2012 edition).2013/5/20
-
WSJ: Novartis said to eye $16B offer for ActavisActavis ($ACT) has suddenly become the belle of the ball. The Wall Street Journal reports that deal talk is heating up, with Novartis ($NVS) said to be entertaining a $16 billion bid for the generics2013/5/17
-
Novo CEO scolds European officials for 'empty promises' on new drugsNovo Nordisk ($NVO) CEO Lars Sørensen says Europe needs to loosen its purse strings to keep drug innovation coming. If austerity-minded governments aren't willing to pay for new drugs, then hi2013/5/17
-
Jury is out in another case linking Novartis' Zometa to jawbone deathNovartis ($NVS) is one step closer to knowing how its latest round of Zometa litigation works out. After 11 days of testimony, the jury has started deliberating its verdict on plaintiff Beverly Meng'2013/5/16
-
Bayer's radiotherapy Xofigo wins FDA nod in prostate cancerThe FDA has hit the green light for Xofigo--initially calledAlpharadinor radium-223 chloride--for castration-resistantprostate cancer. The approval demonstrates the agency's growing comfort with targ2013/5/16
-
Fast cost-cutting puts Merck KGaA a year ahead on financial targetsMerck KGaA is a year ahead of schedule. The German drugmaker, which has been slashing payrolls and shutting facilties to save money, said it would meet its 2014 sales and earnings targets this year i2013/5/15
-
Congressional Repubs challenge FDA on deputy commissioner's exitA revolving door inside the FDA has captured the attention of a group of Republican lawmakers. Just a few months after Leona Brenner-Gati was named Acting Deputy Commissioner for Medical Products and2013/5/15
-
Astellas forecasts big sales growth as prostate drug catches holdJapan's drugmakers aren't any more immune togeneric competition than U.S. pharma companies are. Still, the country's second- and third-largest drugmakers are predicting sales growth this year, even a2013/5/14